|
Gene: FAR2 |
Gene summary for FAR2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | FAR2 | Gene ID | 55711 |
Gene name | fatty acyl-CoA reductase 2 | |
Gene Alias | HEL-S-81 | |
Cytomap | 12p11.22 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A024RAW7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55711 | FAR2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.72e-27 | -7.13e-01 | 0.0155 |
55711 | FAR2 | HTA11_2951_2000001011 | Human | Colorectum | AD | 9.46e-03 | -7.65e-01 | 0.0216 |
55711 | FAR2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.25e-05 | -5.98e-01 | -0.1207 |
55711 | FAR2 | HTA11_696_2000001011 | Human | Colorectum | AD | 6.42e-04 | -3.15e-01 | -0.1464 |
55711 | FAR2 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.28e-15 | -6.47e-01 | 0.096 |
55711 | FAR2 | HTA11_9408_2000001011 | Human | Colorectum | AD | 2.41e-02 | -6.82e-01 | 0.0451 |
55711 | FAR2 | HTA11_8622_2000001021 | Human | Colorectum | SER | 7.63e-03 | -5.84e-01 | 0.0528 |
55711 | FAR2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 5.09e-07 | -4.95e-01 | 0.0338 |
55711 | FAR2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.25e-09 | -4.72e-01 | 0.0674 |
55711 | FAR2 | HTA11_11156_2000001011 | Human | Colorectum | AD | 4.27e-02 | -8.91e-01 | 0.0397 |
55711 | FAR2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 4.94e-03 | -4.68e-01 | 0.0588 |
55711 | FAR2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.13e-22 | -6.14e-01 | 0.294 |
55711 | FAR2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.26e-05 | -6.78e-01 | 0.2585 |
55711 | FAR2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 8.33e-27 | -7.62e-01 | 0.3005 |
55711 | FAR2 | A001-C-207 | Human | Colorectum | FAP | 5.47e-03 | -2.37e-01 | 0.1278 |
55711 | FAR2 | A015-C-203 | Human | Colorectum | FAP | 1.00e-29 | -5.45e-01 | -0.1294 |
55711 | FAR2 | A015-C-204 | Human | Colorectum | FAP | 1.15e-08 | -5.16e-01 | -0.0228 |
55711 | FAR2 | A014-C-040 | Human | Colorectum | FAP | 6.54e-06 | -4.24e-01 | -0.1184 |
55711 | FAR2 | A002-C-201 | Human | Colorectum | FAP | 8.35e-15 | -5.05e-01 | 0.0324 |
55711 | FAR2 | A001-C-119 | Human | Colorectum | FAP | 5.41e-10 | -6.13e-01 | -0.1557 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | |
Endometrium | AEH | |
Endometrium | EEC | |
Prostate | BPH | |
Prostate | Tumor |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0009150 | Colorectum | AD | purine ribonucleotide metabolic process | 142/3918 | 368/18723 | 4.29e-15 | 1.17e-12 | 142 |
GO:0006163 | Colorectum | AD | purine nucleotide metabolic process | 149/3918 | 396/18723 | 1.08e-14 | 2.80e-12 | 149 |
GO:0072521 | Colorectum | AD | purine-containing compound metabolic process | 153/3918 | 416/18723 | 4.34e-14 | 1.01e-11 | 153 |
GO:0009259 | Colorectum | AD | ribonucleotide metabolic process | 144/3918 | 385/18723 | 5.25e-14 | 1.13e-11 | 144 |
GO:0019693 | Colorectum | AD | ribose phosphate metabolic process | 145/3918 | 396/18723 | 3.01e-13 | 5.71e-11 | 145 |
GO:0009117 | Colorectum | AD | nucleotide metabolic process | 168/3918 | 489/18723 | 2.20e-12 | 3.36e-10 | 168 |
GO:0006753 | Colorectum | AD | nucleoside phosphate metabolic process | 169/3918 | 497/18723 | 4.99e-12 | 6.98e-10 | 169 |
GO:0006790 | Colorectum | AD | sulfur compound metabolic process | 101/3918 | 339/18723 | 6.46e-05 | 1.07e-03 | 101 |
GO:0033865 | Colorectum | AD | nucleoside bisphosphate metabolic process | 42/3918 | 128/18723 | 1.12e-03 | 1.02e-02 | 42 |
GO:0033875 | Colorectum | AD | ribonucleoside bisphosphate metabolic process | 42/3918 | 128/18723 | 1.12e-03 | 1.02e-02 | 42 |
GO:0034032 | Colorectum | AD | purine nucleoside bisphosphate metabolic process | 42/3918 | 128/18723 | 1.12e-03 | 1.02e-02 | 42 |
GO:00061631 | Colorectum | SER | purine nucleotide metabolic process | 109/2897 | 396/18723 | 4.26e-10 | 5.44e-08 | 109 |
GO:00091501 | Colorectum | SER | purine ribonucleotide metabolic process | 103/2897 | 368/18723 | 4.69e-10 | 5.68e-08 | 103 |
GO:00725211 | Colorectum | SER | purine-containing compound metabolic process | 113/2897 | 416/18723 | 4.80e-10 | 5.68e-08 | 113 |
GO:00092591 | Colorectum | SER | ribonucleotide metabolic process | 104/2897 | 385/18723 | 3.27e-09 | 3.04e-07 | 104 |
GO:00196931 | Colorectum | SER | ribose phosphate metabolic process | 105/2897 | 396/18723 | 8.15e-09 | 7.14e-07 | 105 |
GO:00091171 | Colorectum | SER | nucleotide metabolic process | 122/2897 | 489/18723 | 2.50e-08 | 1.76e-06 | 122 |
GO:00067531 | Colorectum | SER | nucleoside phosphate metabolic process | 122/2897 | 497/18723 | 6.64e-08 | 4.33e-06 | 122 |
GO:00067901 | Colorectum | SER | sulfur compound metabolic process | 73/2897 | 339/18723 | 1.75e-03 | 1.81e-02 | 73 |
GO:00061632 | Colorectum | MSS | purine nucleotide metabolic process | 128/3467 | 396/18723 | 2.04e-11 | 3.02e-09 | 128 |
Page: 1 2 3 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAR2 | SNV | Missense_Mutation | c.877G>T | p.Ala293Ser | p.A293S | Q96K12 | protein_coding | tolerated(0.06) | benign(0.411) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FAR2 | SNV | Missense_Mutation | novel | c.131T>A | p.Val44Glu | p.V44E | Q96K12 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-BH-A1FR-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
FAR2 | SNV | Missense_Mutation | novel | c.733N>C | p.Asp245His | p.D245H | Q96K12 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
FAR2 | SNV | Missense_Mutation | rs139633375 | c.823N>A | p.Val275Ile | p.V275I | Q96K12 | protein_coding | tolerated(0.35) | benign(0.006) | TCGA-AA-3812-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
FAR2 | SNV | Missense_Mutation | novel | c.47C>T | p.Thr16Met | p.T16M | Q96K12 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FAR2 | SNV | Missense_Mutation | novel | c.526N>C | p.Lys176Gln | p.K176Q | Q96K12 | protein_coding | tolerated(0.17) | possibly_damaging(0.542) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
FAR2 | SNV | Missense_Mutation | c.1187A>G | p.Asn396Ser | p.N396S | Q96K12 | protein_coding | tolerated(0.92) | benign(0.012) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
FAR2 | SNV | Missense_Mutation | c.1100N>G | p.Tyr367Cys | p.Y367C | Q96K12 | protein_coding | tolerated(0.07) | benign(0.082) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
FAR2 | SNV | Missense_Mutation | novel | c.34T>C | p.Ser12Pro | p.S12P | Q96K12 | protein_coding | deleterious(0.01) | possibly_damaging(0.809) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
FAR2 | deletion | Frame_Shift_Del | c.1329delA | p.Lys443AsnfsTer4 | p.K443Nfs*4 | Q96K12 | protein_coding | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |